The group goes after a KRAS-related target on which Boehringer recently gave up.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.

Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.

The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.

First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.

Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.

Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.